Intellia Therapeutics (NTLA) to Announce Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.8017) per share and revenue of $12.98 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same period last year, the firm earned ($1.10) earnings per share. On average, analysts expect Intellia Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Intellia Therapeutics Stock Performance

NASDAQ NTLA opened at $11.32 on Wednesday. The business’s fifty day moving average is $13.79 and its 200 day moving average is $13.50. The company has a market capitalization of $1.58 billion, a PE ratio of -3.20 and a beta of 1.81. Intellia Therapeutics has a fifty-two week low of $7.95 and a fifty-two week high of $28.25.

Insider Activity

In other news, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president owned 156,286 shares in the company, valued at $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Michael P. Dube sold 2,641 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This represents a 3.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of Intellia Therapeutics during the 4th quarter valued at about $245,000. Invesco Ltd. increased its stake in Intellia Therapeutics by 5.8% during the fourth quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock worth $3,895,000 after acquiring an additional 23,870 shares during the last quarter. Axxcess Wealth Management LLC raised its position in Intellia Therapeutics by 20.1% during the fourth quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock valued at $192,000 after purchasing an additional 3,583 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in Intellia Therapeutics during the fourth quarter valued at approximately $90,000. Finally, XTX Topco Ltd bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at approximately $402,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on NTLA shares. Sanford C. Bernstein lifted their price objective on Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Wolfe Research cut shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a research note on Wednesday, July 15th. New Street Research set a $25.00 price target on shares of Intellia Therapeutics in a report on Monday, June 15th. Canaccord Genuity Group reiterated a “buy” rating and issued a $49.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, June 16th. Finally, Leerink Partners set a $35.00 price objective on shares of Intellia Therapeutics in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of “Hold” and an average price target of $20.19.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.